Johnson & Johnson (JNJ)
| Market Cap | 664.95B +48.4% |
| Revenue (ttm) | 99.34B +7.8% |
| Net Income | 16.10B -35.9% |
| EPS | 6.58 -36.4% |
| Shares Out | 2.41B |
| PE Ratio | 41.95 |
| Forward PE | 24.83 |
| Dividend | $5.36 (1.94%) |
| Ex-Dividend Date | Nov 24, 2026 |
| Volume | 8,861,277 |
| Open | 267.56 |
| Previous Close | 272.32 |
| Day's Range | 265.55 - 276.41 |
| 52-Week Range | 185.12 - 282.02 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 279.41 (+1.16%) |
| Earnings Date | Oct 13, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $279.41, which is an increase of 1.16% from the latest price.
News
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
New patient experience data a to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights com...
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ...
J&J's once-daily pill eases psoriatic arthritis symptoms in late-stage trial
Johnson & Johnson said on Saturday its once-daily pill eased symptoms in more patients with psoriatic arthritis than a placebo in a late-stage trial, potentially supporting expanded use of the drug.
Halozyme says Enhanze technology in J&J’s Rybrevant Faspro
Halozyme (HALO) announced that Johnson & Johnson (JNJ) was granted accelerated approval from the Food and Drug Administration for Rybrevant Faspro, which is co-formulated with Enhanze, as a single age...
Healthcare Stocks Fall as Market Rout Spreads
Global healthcare stocks fell Friday, hit by a rout that reached Europe and Asia and spread across sectors after hammering AI trades and U.S. markets earlier in the week.
Johnson & Johnson granted accelerated approval for Rybrevant Faspro
Johnson & Johnson announced that the FDA granted accelerated approval for Rybrevant Faspro as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous…
Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1 First advancement in the...
Johnson & Johnson announce results from three clinical analyses at TCT 2026
Johnson & Johnson announced results from three clinical analyses being presented during the Transcatheter Cardiovascular Therapeutics annual scientific symposium, TCT 2026, that report positive surviv...
Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
SAN DIEGO--(BUSINESS WIRE)-- #PressRelease--Johnson & Johnson announced results from three clinical analyses being presented during the Transcatheter Cardiovascular Therapeutics annual scientific symp...
The big winners of the tech wreck are biopharma stocks
Who would have believed that the boring healthcare industry would be the hottest stock sector of 2026? Companies like Johnson & Johnson, Quest Diagnostics and UnitedHealth Group have long been known f...
The Big 3: AAPL, JNJ, MMM
As a tech selloff sparked by Alphabet (GOOGL) earnings grips the stock market, Dan Deming continues to see the rotation as the biggest unsung headline for equities. As for today's Big 3, he expects Ap...
Oric Pharmaceuticals price target lowered to $14 from $17 at Wedbush
Wedbush lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $14 from $17 and keeps an Outperform rating on the shares. Relevant to Oric’s rinzimetostat, Johnson & Johnson (JNJ)…
Johnson & Johnson to Host Enterprise Business Review
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will hold an Enterprise Business Review for the investment community on Tuesday, December 8th, 2026. During the event, Company leade...
Oric Pharmaceuticals selloff brings buying opportunity, says Jones
Jones views the selloff yesterday in shares of Oric Pharmaceuticals (ORIC) as a buying opportunity. Oric was under pressure on the back of Johnson & Johnson’s (JNJ) positive data with…
Oric Pharmaceuticals drops after J&J presents prostate cancer drug data
Shares of drug developer Oric Pharmaceuticals (ORIC) are falling after competitor Johnson & Johnson (JNJ) presented data about its own potential drug to treat patients with prostate cancer at a…
Johnson & Johnson announces Phase 1 results for JNJ-6143 at ESMO 2026
Johnson & Johnson announced Phase 1 results for JNJ-6143, an investigational once-daily oral Regulated Induced Proximity Targeting Chimera small molecule, in patients with advanced prostate cancer who...
Johnson & Johnson announces results from Cohort 5 of Phase 1b/2 OrigAMI-4 study
Johnson & Johnson announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study showing deep and durable responses with first-line subcutaneous amivantamab and hyaluronidase-lpuj plus a PD-1 i...
Johnson & Johnson announces results from Phase 3 PROTEUS substudy
Johnson & Johnson announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy, ADT, given for six months bef...
Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer
BEERSE, BELGIUM, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study with first-line subcutaneous RYBREVANT®▼ (amivantamab) ...
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 study Data h...
Johnson & Johnson (JNJ) Reports 69% Tumor Response Rate for Prostate Cancer Drug
Johnson & Johnson ($JNJ) has reported promising early results for its experimental prostate cancer pill, JNJ-6143, which has excited the oncology world. In a trial involving patients with advanced pro...
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed tumo...
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer
BEERSE, BELGIUM , Oct. 24, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus h...
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ADT compared with immediate surgery Twice as many patients remained free fro...
Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial
Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to disappear or shrink in an early-stage trial.